Heterodimeric antibodies that bind CD3 and CLDN6
US11739144B2 · kind B2 · utility
0Cited by
130References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 9, 2022 |
| Grant date | Aug 29, 2023 |
| Priority date | — |
| Expiry date | Apr 14, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.